Insiders selling shares without any recorded purchases over the last year raises caution. The alignment between management and smaller shareholders due to insider ownership is not outstanding. Caution is advised before buying shares in Blueprint Medicines due to significant selling activity.
The stock's commendable performance is tied to revenue growth. However, profitability and cash flow checks are crucial for future views. Given the strong share price momentum, the stock warrants a closer look.
Blueprint Medicines' high P/S ratio is worrisome due to its lower projected growth compared to the broader industry. If future revenues don't support this optimism, the current high P/S ratio may not be sustainable. Prices may not be reasonable unless conditions significantly improve.
Blueprint Medicines' increased debt brings a heightened risk profile due to last year's dilution in revenues and lack of profitability. Its future earnings and balance sheet health are key to assessing risk.
Significant sale by President of R&D Fouad Namouni implies shares may not be undervalued. This, along with multiple insider sales, is a potential red flag for investors.
The significant fall in both the share price and revenue of Blueprint Medicines Corporation could indicate unresolved issues within the company. The continued lack of profitability may also be a concern for long-term investors.
ブループリント・メディスンに関するコメント
Extended Hours Top Moovers.
📊⚡️📊
Updated Complete & Utter M&A Guesses Purely for Entertainment Purposes:
$メルク(MRK.US)$ x $イムノバント(IMVT.US)$
$イーライリリー(LLY.US)$ x $サイトカイネティックス(CYTK.US)$ (and soon)
$リジェネロン・ファーマシューティカルズ(REGN.US)$ x $アペリス・ファーマシューティカルズ(APLS.US)$ (panache & brash)
$ギリアド・サイエンシズ(GILD.US)$ x %$マドリガル・ファーマシューティカルズ(MDGL.US)$ (liver king)
$ブリストル・マイヤーズ スクイブ(BMY.US)$ x $アイオバンス・バイオセラピューティクス(IOVA.US)$ (cell Tx boost needed)
$イーライリリー(LLY.US)$ x $メルス(MRUS.US)$ (partner n...
コラムTop upgrades and downgrades on 7/8: PYPL, UPST, AAL, RCKT and more
• $ビタ・ココ・カンパニー(COCO.US)$ : BofA Securities Upgrades to Buy from Neutral - PT $12 (from $10)
• $Diebold Nixdorf(DBD.US)$ : Wedbush Upgrades to Outperform from Neutral - PT $5
• $エバーソース・エナジー(ES.US)$ : Guggenheim Upgrades to Buy from Neutral - PT $97 (from $92)
• $ハウメット・エアロスペース(HWM.US)$ : Benchmark Upgrades to Buy from Neutral - PT $40
• $インターパブリック・グループ・オブ・カンパニーズ(IPG.US)$ : Wells Fargo Upgrades to Overweight...
コラムTop upgrades and downgrades on 6/27: ETSY, CHWY, BBBY, GTLB and more
• $オートゾーン(AZO.US)$ : Goldman Sachs Upgrades to Buy from Neutral - PT $2,296 (from $1,969)
• $チューイー(CHWY.US)$ : Needham Upgrades to Buy from Hold - PT $55
• $ナショナル・ビジョン・ホールディングス(EYE.US)$ : Goldman Sachs Upgrades to Buy from Neutral - PT $32 (from $31)
• $フレゼニウス・メディカル・ケア(FMS.US)$ : Jefferies Upgrades to Buy from Underperform - PT $33.70 (from $30.30)
• $ギットラブ(GTLB.US)$ : Goldman Sachs Upgrades to Buy from Neutral - ...
まだコメントはありません